following a full submission assessed under the orphan medicine process:
alectinib (Alecensa®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Alectinib, compared with another tyrosine kinase inhibitor, significantly improved progression-free survival in treatment-naïve adults with advanced or recurrent ALK-positive NSCLC.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of alectinib. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
Download detailed advice125KB (PDF)
- Medicine name:
- alectinib hydrochloride (Alecensa)
- SMC ID:
- As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
- Pharmaceutical company
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 13 August 2018